Ikarian Capital, LLC Beam Therapeutics Inc. Transaction History
Ikarian Capital, LLC
- $714 Million
- Q1 2025
A detailed history of Ikarian Capital, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 360,000 shares of BEAM stock, worth $6.2 Million. This represents 0.97% of its overall portfolio holdings.
Number of Shares
360,000Holding current value
$6.2 Million% of portfolio
0.97%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BEAM
# of Institutions
258Shares Held
93.6MCall Options Held
425KPut Options Held
309K-
Farallon Capital Management LLC San Francisco, CA9.93MShares$171 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.87MShares$153 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.48MShares$146 Million1.79% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$131 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$78.2 Million72.77% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.21B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...